Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Exelixis (EXEL) and CSL Limited Sponsored ADR (CSLLY) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out. The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The proven Zacks Rank emphasizes companies with positive estimate revision trends, and our Styl ...

Exelixis' (EXEL) shares have risen 14.9% in a week after the company reported better-than-expected secondquarter results on Aug 6. The industry grew 0.7% during the said timeframe. It was a good quarter for Exelixis not just in terms of earnings and sales beat as the company made encouraging pipeline progress too which impressed investors. Image Source: Zacks Investment Research Earnings per share of 84 cents comfortably surpassed the Zacks Consensus Estimate of 37 cents, on the back of higher revenues and ...

Have you looked into how Exelixis (EXEL) performed internationally during the quarter ending June 2024? Considering the widespread global presence of this drug developer, examining the trends in international revenues is essential for assessing its financial resilience and prospects for growth. In the current global economy, which is more interconnected than ever, a company's success in penetrating international markets is crucial for its financial health and growth journey. Investors must understand a comp ...

le l 1 IDH Morsa Images Exelixis, Inc. (NASDAQ:EXEL) released its earnings report for its second-quarter 2024 earnings. Investors should look into this name because Cabometyx has been holding strong in treating patients with Renal Cell Carcinoma [RCC]. Matter of fact, U.S. net product revenues grew by 16% quarter over quarter. Furthermore, a 7% growth of this was attributed year over year as well. Revenue for this franchise is coming along so well that it was able to receive a $150 million sales-based miles ...

Exelixis, Inc. (EXEL) reported better-than-expected second-quarter results. Shares have risen following the announcement. EXEL recorded earnings of 84 cents per share, which beat the Zacks Consensus Estimate of 37 cents. The company registered adjusted earnings of 31 cents per share in the second quarter of 2023. The upside is mainly driven by higher revenues and lower operating expenses. Including stock-based compensation expense, earnings were 77 cents per share in the reported quarter. Net revenues were ...

In its second-quarter earnings release, Exelixis, Inc. EXEL announced that the final overall survival (OS) analysis for the phase 3 CONTACT-02 trial has been completed. This study evaluates cabozantinib in combination with atezolizumab compared with a second novel hormonal therapy (NHT) in patients with metastatic castration-resistant prostate cancer (mCRPC) and measurable softtissue disease who have progressed after treatment with one prior NHT. Also Read: Bristol Myers, Exelixis Reveal 4-Year Follow-Up Re ...

Exelixis, Inc. (NASDAQ:EXEL) Q2 2024 Earnings Conference Call August 6, 2024 5:00 PM ET Company Participants Susan Hubbard - Executive Vice President, Public Affairs and Investor Relations Michael Morrissey - President and Chief Executive Officer Christopher Senner - Executive Vice President and Chief Financial Officer Amy Peterson - Executive Vice President, Product Development, Medical Affairs and Chief Medical Officer Dana Aftab - Chief Scientific Officer P.J. Haley - Executive Vice President of Commerci ...

Exelixis (EXEL) reported $637.18 million in revenue for the quarter ended June 2024, representing a year-overyear increase of 35.6%. EPS of $0.84 for the same period compares to $0.31 a year ago. The reported revenue represents a surprise of +36.09% over the Zacks Consensus Estimate of $468.21 million. With the consensus EPS estimate being $0.37, the EPS surprise was +127.03%. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determi ...

Exelixis (EXEL) came out with quarterly earnings of $0.84 per share, beating the Zacks Consensus Estimate of $0.37 per share. This compares to earnings of $0.31 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of 127.03%. A quarter ago, it was expected that this drug developer would post earnings of $0.28 per share when it actually produced earnings of $0.17, delivering a surprise of -39.29%. Over the last four quarters, the compa ...

Exhibit 99.1 Contacts: Chris Senner Chief Financial Officer Exelixis, Inc. 650-837-7240 csenner@exelixis.com Susan Hubbard EVP, Public Affairs & Investor Relations Exelixis, Inc. 650-837-8194 shubbard@exelixis.com Exelixis Announces Second Quarter 2024 Financial Results and Provides Corporate Update - Total Revenues of $637.2 million, Cabozantinib Franchise U.S. Net Product Revenues of $437.6 million - - GAAP Diluted EPS of $0.77, Non-GAAP Diluted EPS of $0.84 - - U.S. Food and Drug Administration (FDA) Acc ...